Kathryn Colborn
Concepts (464)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 14 | 2025 | 1210 | 3.870 |
Why?
| | Postoperative Complications | 34 | 2026 | 3034 | 2.860 |
Why?
| | Machine Learning | 11 | 2026 | 594 | 2.250 |
Why?
| | Surgical Wound Infection | 8 | 2025 | 349 | 1.790 |
Why?
| | Models, Statistical | 6 | 2026 | 669 | 1.570 |
Why?
| | Surgical Procedures, Operative | 7 | 2026 | 307 | 1.460 |
Why?
| | Urinary Tract Infections | 4 | 2025 | 209 | 1.320 |
Why?
| | Sepsis | 7 | 2025 | 669 | 1.300 |
Why?
| | Shock, Septic | 5 | 2025 | 230 | 1.270 |
Why?
| | Pancreatic Neoplasms | 11 | 2025 | 944 | 1.190 |
Why?
| | Quality Improvement | 15 | 2026 | 1354 | 1.160 |
Why?
| | Malaria | 4 | 2023 | 73 | 0.980 |
Why?
| | Quality of Life | 14 | 2026 | 3200 | 0.950 |
Why?
| | Law Enforcement | 1 | 2025 | 52 | 0.880 |
Why?
| | Retrospective Studies | 51 | 2026 | 17438 | 0.880 |
Why?
| | Police | 1 | 2025 | 51 | 0.870 |
Why?
| | Humans | 142 | 2026 | 146342 | 0.850 |
Why?
| | Databases, Factual | 16 | 2025 | 1493 | 0.730 |
Why?
| | Postoperative Hemorrhage | 2 | 2023 | 106 | 0.720 |
Why?
| | Risk Assessment | 20 | 2026 | 3712 | 0.720 |
Why?
| | Pneumonia | 4 | 2025 | 635 | 0.710 |
Why?
| | Malaria, Falciparum | 2 | 2018 | 32 | 0.700 |
Why?
| | Palliative Care | 10 | 2026 | 1032 | 0.670 |
Why?
| | Emergency Service, Hospital | 5 | 2025 | 2363 | 0.670 |
Why?
| | Plasmodium vivax | 2 | 2018 | 6 | 0.640 |
Why?
| | Malaria, Vivax | 2 | 2018 | 4 | 0.640 |
Why?
| | Pain | 2 | 2023 | 790 | 0.630 |
Why?
| | Breast Neoplasms | 8 | 2026 | 2418 | 0.630 |
Why?
| | Middle Aged | 47 | 2026 | 36619 | 0.610 |
Why?
| | Aged | 39 | 2026 | 26432 | 0.610 |
Why?
| | Adenocarcinoma | 5 | 2024 | 927 | 0.600 |
Why?
| | Female | 69 | 2026 | 79499 | 0.600 |
Why?
| | Patient Reported Outcome Measures | 7 | 2024 | 516 | 0.570 |
Why?
| | Male | 61 | 2026 | 73396 | 0.560 |
Why?
| | Preoperative Care | 5 | 2026 | 396 | 0.560 |
Why?
| | Surgeons | 4 | 2025 | 351 | 0.550 |
Why?
| | Inpatients | 4 | 2023 | 540 | 0.550 |
Why?
| | Mastectomy | 5 | 2026 | 189 | 0.530 |
Why?
| | Artificial Intelligence | 1 | 2023 | 389 | 0.530 |
Why?
| | Poisson Distribution | 1 | 2018 | 77 | 0.530 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 37 | 0.530 |
Why?
| | Thoracic Surgery | 3 | 2025 | 145 | 0.530 |
Why?
| | Health Plan Implementation | 1 | 2019 | 143 | 0.520 |
Why?
| | Risk Factors | 26 | 2026 | 10921 | 0.500 |
Why?
| | Neoadjuvant Therapy | 8 | 2024 | 475 | 0.500 |
Why?
| | Adult | 42 | 2026 | 41087 | 0.490 |
Why?
| | Mosquito Control | 2 | 2023 | 30 | 0.480 |
Why?
| | Hospitalization | 7 | 2025 | 2475 | 0.480 |
Why?
| | Algorithms | 5 | 2025 | 1849 | 0.460 |
Why?
| | Mosquito Nets | 1 | 2015 | 2 | 0.450 |
Why?
| | Child, Preschool | 19 | 2026 | 11913 | 0.440 |
Why?
| | Anopheles | 1 | 2015 | 18 | 0.440 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2023 | 297 | 0.430 |
Why?
| | Drug Prescriptions | 3 | 2021 | 314 | 0.410 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2023 | 370 | 0.400 |
Why?
| | Risk Adjustment | 2 | 2025 | 86 | 0.400 |
Why?
| | Thoracic Surgical Procedures | 2 | 2025 | 98 | 0.370 |
Why?
| | Mastectomy, Segmental | 2 | 2024 | 107 | 0.360 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2023 | 82 | 0.360 |
Why?
| | Primary Health Care | 3 | 2025 | 1776 | 0.360 |
Why?
| | Patient Discharge | 2 | 2020 | 997 | 0.350 |
Why?
| | Hospital Mortality | 1 | 2016 | 1051 | 0.340 |
Why?
| | Decision Support Systems, Clinical | 2 | 2026 | 279 | 0.330 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 115 | 0.330 |
Why?
| | Infant | 14 | 2026 | 10114 | 0.320 |
Why?
| | Robotic Surgical Procedures | 2 | 2024 | 210 | 0.320 |
Why?
| | Influenza, Human | 3 | 2021 | 640 | 0.310 |
Why?
| | Incidence | 8 | 2023 | 2936 | 0.300 |
Why?
| | Hospitals | 4 | 2025 | 738 | 0.300 |
Why?
| | Emergency Treatment | 2 | 2021 | 122 | 0.300 |
Why?
| | Zebrafish | 2 | 2025 | 536 | 0.290 |
Why?
| | Pancreatectomy | 4 | 2025 | 289 | 0.290 |
Why?
| | Heart Failure | 5 | 2025 | 2329 | 0.290 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 634 | 0.290 |
Why?
| | Colorado | 9 | 2025 | 4595 | 0.280 |
Why?
| | United States | 20 | 2025 | 16136 | 0.270 |
Why?
| | Aged, 80 and over | 11 | 2025 | 8391 | 0.270 |
Why?
| | Research Design | 3 | 2022 | 1143 | 0.260 |
Why?
| | Cohort Studies | 11 | 2024 | 6077 | 0.260 |
Why?
| | Longitudinal Studies | 5 | 2026 | 3017 | 0.260 |
Why?
| | Adolescent | 16 | 2026 | 22557 | 0.260 |
Why?
| | Logistic Models | 5 | 2023 | 2126 | 0.250 |
Why?
| | Osteoarthritis, Knee | 2 | 2021 | 291 | 0.250 |
Why?
| | Preoperative Period | 2 | 2025 | 157 | 0.250 |
Why?
| | Patient Satisfaction | 4 | 2024 | 706 | 0.250 |
Why?
| | Chagas Disease | 2 | 2018 | 41 | 0.250 |
Why?
| | Asthma | 1 | 2019 | 1800 | 0.250 |
Why?
| | Seasons | 3 | 2025 | 540 | 0.250 |
Why?
| | Child | 16 | 2026 | 22693 | 0.240 |
Why?
| | Cardiac Surgical Procedures | 2 | 2023 | 611 | 0.240 |
Why?
| | Autism Spectrum Disorder | 2 | 2023 | 406 | 0.240 |
Why?
| | Proportional Hazards Models | 3 | 2026 | 1331 | 0.240 |
Why?
| | Mass Drug Administration | 3 | 2023 | 7 | 0.240 |
Why?
| | Prognosis | 10 | 2024 | 4351 | 0.240 |
Why?
| | Guideline Adherence | 3 | 2026 | 594 | 0.240 |
Why?
| | Rectal Neoplasms | 2 | 2019 | 160 | 0.240 |
Why?
| | Patient Care Bundles | 1 | 2026 | 30 | 0.240 |
Why?
| | Bayes Theorem | 2 | 2026 | 426 | 0.230 |
Why?
| | Varenicline | 1 | 2025 | 29 | 0.230 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2021 | 385 | 0.230 |
Why?
| | Markov Chains | 1 | 2026 | 129 | 0.230 |
Why?
| | Monte Carlo Method | 1 | 2026 | 151 | 0.230 |
Why?
| | Survival Analysis | 2 | 2026 | 1378 | 0.220 |
Why?
| | Tobacco Use Cessation | 1 | 2025 | 28 | 0.220 |
Why?
| | Intracranial Pressure | 1 | 2026 | 64 | 0.220 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2024 | 429 | 0.220 |
Why?
| | Elective Surgical Procedures | 2 | 2024 | 216 | 0.220 |
Why?
| | Time-to-Treatment | 2 | 2025 | 257 | 0.220 |
Why?
| | Craniofacial Abnormalities | 1 | 2025 | 78 | 0.210 |
Why?
| | CA-19-9 Antigen | 1 | 2024 | 36 | 0.210 |
Why?
| | Varicose Veins | 1 | 2024 | 16 | 0.200 |
Why?
| | Catheterization, Peripheral | 1 | 2025 | 116 | 0.200 |
Why?
| | Treatment Outcome | 13 | 2025 | 11821 | 0.200 |
Why?
| | Antimicrobial Stewardship | 1 | 2026 | 136 | 0.200 |
Why?
| | Artemisinins | 2 | 2023 | 5 | 0.200 |
Why?
| | Anti-Infective Agents | 2 | 2026 | 234 | 0.190 |
Why?
| | Heart Defects, Congenital | 2 | 2022 | 923 | 0.190 |
Why?
| | Metastasectomy | 1 | 2023 | 19 | 0.190 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 38 | 0.190 |
Why?
| | Specialties, Surgical | 2 | 2021 | 88 | 0.190 |
Why?
| | Hypothermia | 1 | 2023 | 53 | 0.190 |
Why?
| | Multivariate Analysis | 2 | 2023 | 1543 | 0.190 |
Why?
| | Zebrafish Proteins | 2 | 2025 | 314 | 0.190 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 38 | 0.190 |
Why?
| | Predictive Value of Tests | 4 | 2022 | 2113 | 0.190 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 63 | 0.190 |
Why?
| | Behavior Therapy | 1 | 2025 | 291 | 0.180 |
Why?
| | MEF2 Transcription Factors | 1 | 2022 | 51 | 0.180 |
Why?
| | Insecticides | 1 | 2023 | 44 | 0.180 |
Why?
| | Europe | 1 | 2023 | 421 | 0.180 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 71 | 0.180 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2023 | 74 | 0.180 |
Why?
| | Patient Participation | 1 | 2026 | 457 | 0.180 |
Why?
| | Telemetry | 1 | 2022 | 41 | 0.180 |
Why?
| | Medication Therapy Management | 1 | 2023 | 73 | 0.180 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 49 | 0.180 |
Why?
| | Microcephaly | 1 | 2023 | 106 | 0.180 |
Why?
| | Young Adult | 11 | 2020 | 14330 | 0.180 |
Why?
| | Nervous System Diseases | 1 | 2025 | 288 | 0.180 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 1221 | 0.180 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1408 | 0.180 |
Why?
| | Syncope | 1 | 2022 | 48 | 0.180 |
Why?
| | Polypharmacy | 1 | 2023 | 94 | 0.180 |
Why?
| | Quinolines | 2 | 2023 | 191 | 0.180 |
Why?
| | Carotid Stenosis | 1 | 2023 | 103 | 0.180 |
Why?
| | Hospitals, Pediatric | 1 | 2025 | 561 | 0.180 |
Why?
| | Galectins | 1 | 2022 | 25 | 0.170 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 44 | 0.170 |
Why?
| | Information Dissemination | 1 | 2024 | 226 | 0.170 |
Why?
| | Anti-Bacterial Agents | 4 | 2025 | 1942 | 0.170 |
Why?
| | Pneumonectomy | 1 | 2023 | 169 | 0.170 |
Why?
| | Decision Support Techniques | 1 | 2026 | 478 | 0.170 |
Why?
| | Drug Hypersensitivity | 1 | 2023 | 93 | 0.170 |
Why?
| | Smoking Cessation | 1 | 2025 | 442 | 0.170 |
Why?
| | Ivermectin | 1 | 2021 | 15 | 0.170 |
Why?
| | Mozambique | 2 | 2018 | 7 | 0.170 |
Why?
| | Delirium | 1 | 2023 | 107 | 0.170 |
Why?
| | Computer Simulation | 1 | 2026 | 1014 | 0.170 |
Why?
| | Precision Medicine | 1 | 2025 | 462 | 0.170 |
Why?
| | Neuroendocrine Tumors | 1 | 2023 | 122 | 0.170 |
Why?
| | Program Evaluation | 3 | 2021 | 952 | 0.160 |
Why?
| | Internet | 1 | 2025 | 660 | 0.160 |
Why?
| | Dysbiosis | 1 | 2022 | 184 | 0.160 |
Why?
| | Oxycodone | 1 | 2021 | 53 | 0.160 |
Why?
| | New Guinea | 2 | 2018 | 3 | 0.160 |
Why?
| | Gastric Bypass | 1 | 2022 | 115 | 0.160 |
Why?
| | Surgery Department, Hospital | 1 | 2020 | 23 | 0.160 |
Why?
| | Vascular Surgical Procedures | 1 | 2024 | 352 | 0.160 |
Why?
| | Communication | 2 | 2025 | 980 | 0.160 |
Why?
| | Ambulatory Care | 1 | 2025 | 628 | 0.160 |
Why?
| | Adaptation, Psychological | 1 | 2025 | 721 | 0.160 |
Why?
| | Knee Joint | 2 | 2021 | 453 | 0.160 |
Why?
| | Hypersensitivity | 1 | 2023 | 253 | 0.150 |
Why?
| | Arthroplasty | 1 | 2020 | 60 | 0.150 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 46 | 0.150 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2022 | 248 | 0.150 |
Why?
| | Faculty | 1 | 2021 | 152 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2025 | 1763 | 0.150 |
Why?
| | Qualitative Research | 2 | 2025 | 1734 | 0.150 |
Why?
| | Phenotype | 2 | 2025 | 3206 | 0.150 |
Why?
| | Terminal Care | 1 | 2023 | 284 | 0.150 |
Why?
| | Antimalarials | 1 | 2019 | 35 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1998 | 0.150 |
Why?
| | Brain Injuries, Traumatic | 1 | 2026 | 466 | 0.150 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2019 | 143 | 0.150 |
Why?
| | Telemedicine | 2 | 2025 | 966 | 0.140 |
Why?
| | Waiting Lists | 2 | 2021 | 251 | 0.140 |
Why?
| | Latent Tuberculosis | 1 | 2010 | 71 | 0.140 |
Why?
| | Prisons | 1 | 2010 | 88 | 0.140 |
Why?
| | Feedback | 3 | 2026 | 183 | 0.140 |
Why?
| | Intensive Care Units | 2 | 2022 | 925 | 0.140 |
Why?
| | Vaccination | 2 | 2025 | 1449 | 0.140 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 87 | 0.140 |
Why?
| | Aftercare | 1 | 2020 | 225 | 0.140 |
Why?
| | Laparoscopy | 1 | 2023 | 487 | 0.140 |
Why?
| | Datasets as Topic | 1 | 2019 | 120 | 0.140 |
Why?
| | Organ Transplantation | 1 | 2021 | 244 | 0.140 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 332 | 0.140 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 208 | 0.140 |
Why?
| | Social Marketing | 1 | 2008 | 14 | 0.140 |
Why?
| | Healthcare Disparities | 3 | 2025 | 733 | 0.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1591 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 881 | 0.140 |
Why?
| | Ventricular Function | 1 | 2018 | 53 | 0.140 |
Why?
| | Hospitals, University | 1 | 2018 | 178 | 0.140 |
Why?
| | Prospective Studies | 7 | 2026 | 8123 | 0.140 |
Why?
| | Soft Tissue Infections | 1 | 2008 | 42 | 0.140 |
Why?
| | Developed Countries | 1 | 2018 | 38 | 0.140 |
Why?
| | Outpatients | 1 | 2022 | 440 | 0.140 |
Why?
| | Triage | 1 | 2021 | 243 | 0.130 |
Why?
| | General Surgery | 1 | 2021 | 217 | 0.130 |
Why?
| | Community Participation | 1 | 2019 | 128 | 0.130 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 449 | 0.130 |
Why?
| | Computers, Handheld | 1 | 2018 | 26 | 0.130 |
Why?
| | Climate | 1 | 2018 | 79 | 0.130 |
Why?
| | Obesity, Morbid | 1 | 2022 | 287 | 0.130 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 172 | 0.130 |
Why?
| | Population Groups | 1 | 2018 | 55 | 0.130 |
Why?
| | Reproductive Medicine | 1 | 2008 | 19 | 0.130 |
Why?
| | Defibrillators, Implantable | 1 | 2022 | 393 | 0.130 |
Why?
| | Autistic Disorder | 1 | 2020 | 216 | 0.130 |
Why?
| | Rural Population | 2 | 2020 | 677 | 0.130 |
Why?
| | Geography | 1 | 2018 | 187 | 0.130 |
Why?
| | Sentinel Surveillance | 1 | 2017 | 48 | 0.130 |
Why?
| | Cognition | 2 | 2023 | 1292 | 0.130 |
Why?
| | Condoms | 1 | 2008 | 99 | 0.130 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2019 | 102 | 0.130 |
Why?
| | Immunoglobulin A | 1 | 2019 | 205 | 0.130 |
Why?
| | Patient Admission | 1 | 2019 | 216 | 0.130 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2023 | 118 | 0.130 |
Why?
| | ROC Curve | 1 | 2019 | 617 | 0.130 |
Why?
| | Burns | 1 | 2022 | 365 | 0.130 |
Why?
| | Safety-net Providers | 1 | 2019 | 133 | 0.130 |
Why?
| | Patient Compliance | 1 | 2021 | 589 | 0.130 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 344 | 0.120 |
Why?
| | Occupational Health | 1 | 2010 | 212 | 0.120 |
Why?
| | Lymph Node Excision | 3 | 2023 | 174 | 0.120 |
Why?
| | Anxiety Disorders | 1 | 2010 | 354 | 0.120 |
Why?
| | Gastroenteritis | 1 | 2017 | 63 | 0.120 |
Why?
| | Epidemics | 1 | 2018 | 97 | 0.120 |
Why?
| | Recovery of Function | 1 | 2021 | 725 | 0.120 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 131 | 0.120 |
Why?
| | Cell Phone | 1 | 2017 | 83 | 0.120 |
Why?
| | Influenza Vaccines | 1 | 2021 | 544 | 0.120 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 75 | 0.120 |
Why?
| | Students, Medical | 1 | 2021 | 383 | 0.120 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 495 | 0.120 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 105 | 0.120 |
Why?
| | Occupational Exposure | 1 | 2010 | 356 | 0.120 |
Why?
| | HIV Infections | 2 | 2025 | 3215 | 0.120 |
Why?
| | Parents | 1 | 2025 | 1394 | 0.120 |
Why?
| | Forecasting | 1 | 2018 | 388 | 0.120 |
Why?
| | Fever | 1 | 2017 | 322 | 0.120 |
Why?
| | Melanoma | 1 | 2022 | 765 | 0.120 |
Why?
| | Patient Readmission | 2 | 2020 | 778 | 0.110 |
Why?
| | Surveys and Questionnaires | 6 | 2026 | 6073 | 0.110 |
Why?
| | Alcoholism | 1 | 2023 | 830 | 0.110 |
Why?
| | Morbidity | 3 | 2022 | 319 | 0.110 |
Why?
| | Models, Organizational | 1 | 2016 | 145 | 0.110 |
Why?
| | Nurse Practitioners | 1 | 2018 | 141 | 0.110 |
Why?
| | Cystic Fibrosis | 1 | 2025 | 1164 | 0.110 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5439 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2022 | 806 | 0.110 |
Why?
| | Humidity | 1 | 2015 | 50 | 0.110 |
Why?
| | Mobile Applications | 1 | 2017 | 196 | 0.110 |
Why?
| | Mass Screening | 2 | 2020 | 1307 | 0.110 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 892 | 0.110 |
Why?
| | Indians, North American | 1 | 2009 | 527 | 0.110 |
Why?
| | Diarrhea | 3 | 2023 | 190 | 0.110 |
Why?
| | Antibodies, Viral | 1 | 2019 | 689 | 0.110 |
Why?
| | Massage | 2 | 2010 | 42 | 0.110 |
Why?
| | Pandemics | 4 | 2025 | 1707 | 0.100 |
Why?
| | Advance Care Planning | 1 | 2018 | 244 | 0.100 |
Why?
| | Cannabidiol | 1 | 2016 | 142 | 0.100 |
Why?
| | Family Practice | 1 | 2018 | 422 | 0.100 |
Why?
| | Time Factors | 5 | 2024 | 7109 | 0.100 |
Why?
| | Anticonvulsants | 1 | 2016 | 253 | 0.100 |
Why?
| | Stroke | 1 | 2023 | 1287 | 0.100 |
Why?
| | Models, Biological | 1 | 2021 | 1761 | 0.100 |
Why?
| | Survival Rate | 3 | 2024 | 2092 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1998 | 0.100 |
Why?
| | Neoplasms | 2 | 2025 | 2954 | 0.100 |
Why?
| | Parasitemia | 1 | 2013 | 15 | 0.100 |
Why?
| | Emergency Medical Services | 1 | 2021 | 680 | 0.100 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 560 | 0.100 |
Why?
| | Environmental Exposure | 1 | 2018 | 578 | 0.100 |
Why?
| | Research | 1 | 2016 | 421 | 0.100 |
Why?
| | Chronic Pain | 1 | 2018 | 304 | 0.090 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1215 | 0.090 |
Why?
| | Software | 1 | 2018 | 676 | 0.090 |
Why?
| | Medicaid | 1 | 2017 | 477 | 0.090 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 572 | 0.090 |
Why?
| | Diagnostic Tests, Routine | 2 | 2024 | 109 | 0.090 |
Why?
| | Axilla | 2 | 2023 | 51 | 0.090 |
Why?
| | Temperature | 1 | 2015 | 635 | 0.090 |
Why?
| | Washington | 2 | 2025 | 157 | 0.090 |
Why?
| | Emergencies | 2 | 2025 | 177 | 0.090 |
Why?
| | Epilepsy | 1 | 2016 | 400 | 0.090 |
Why?
| | Patients | 2 | 2023 | 183 | 0.090 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 417 | 0.090 |
Why?
| | Age Factors | 4 | 2021 | 3347 | 0.080 |
Why?
| | Uganda | 2 | 2023 | 91 | 0.080 |
Why?
| | Prevalence | 3 | 2023 | 2861 | 0.080 |
Why?
| | Pain Management | 2 | 2010 | 421 | 0.080 |
Why?
| | Lymphatic Metastasis | 2 | 2023 | 335 | 0.080 |
Why?
| | Disease Progression | 1 | 2019 | 2867 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2921 | 0.080 |
Why?
| | Neoplasm Staging | 2 | 2025 | 1488 | 0.080 |
Why?
| | Heart Transplantation | 1 | 2017 | 682 | 0.080 |
Why?
| | Internship and Residency | 1 | 2021 | 1281 | 0.080 |
Why?
| | Laboratories | 2 | 2021 | 109 | 0.080 |
Why?
| | Postoperative Period | 2 | 2021 | 355 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2219 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2675 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 947 | 0.070 |
Why?
| | Guatemala | 2 | 2023 | 349 | 0.070 |
Why?
| | Societies, Medical | 2 | 2024 | 907 | 0.070 |
Why?
| | Lymph Nodes | 2 | 2023 | 511 | 0.070 |
Why?
| | Feeding Behavior | 1 | 2015 | 692 | 0.070 |
Why?
| | Administration, Oral | 2 | 2025 | 872 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 2016 | 914 | 0.070 |
Why?
| | Piperazines | 2 | 2023 | 368 | 0.070 |
Why?
| | Biomedical Research | 2 | 2025 | 729 | 0.070 |
Why?
| | Immunization Programs | 1 | 2009 | 194 | 0.060 |
Why?
| | Comorbidity | 2 | 2022 | 1665 | 0.060 |
Why?
| | Echocardiography | 2 | 2022 | 645 | 0.060 |
Why?
| | School Health Services | 1 | 2009 | 218 | 0.060 |
Why?
| | Urban Population | 2 | 2020 | 497 | 0.060 |
Why?
| | Insurance Coverage | 2 | 2017 | 248 | 0.060 |
Why?
| | Nebraska | 1 | 2025 | 21 | 0.060 |
Why?
| | Length of Stay | 2 | 2023 | 1358 | 0.060 |
Why?
| | Affect | 1 | 2008 | 318 | 0.060 |
Why?
| | Wyoming | 1 | 2025 | 27 | 0.060 |
Why?
| | Referral and Consultation | 2 | 2023 | 881 | 0.060 |
Why?
| | India | 1 | 2025 | 213 | 0.060 |
Why?
| | Pilot Projects | 2 | 2023 | 1888 | 0.050 |
Why?
| | Administration, Intravenous | 1 | 2025 | 172 | 0.050 |
Why?
| | Glasgow Coma Scale | 1 | 2026 | 211 | 0.050 |
Why?
| | Cytokines | 2 | 2023 | 2081 | 0.050 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1327 | 0.050 |
Why?
| | Infant, Newborn | 3 | 2022 | 6460 | 0.050 |
Why?
| | Acute Disease | 2 | 2017 | 1038 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5899 | 0.050 |
Why?
| | Monitoring, Physiologic | 1 | 2026 | 279 | 0.050 |
Why?
| | Propensity Score | 1 | 2026 | 376 | 0.050 |
Why?
| | Health Care Surveys | 2 | 2010 | 541 | 0.050 |
Why?
| | Body Mass Index | 2 | 2023 | 2458 | 0.050 |
Why?
| | Animals | 4 | 2025 | 38106 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2024 | 222 | 0.050 |
Why?
| | Motivational Interviewing | 1 | 2025 | 121 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 16 | 0.050 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2023 | 135 | 0.050 |
Why?
| | Sternotomy | 1 | 2022 | 25 | 0.050 |
Why?
| | Growth Disorders | 1 | 2023 | 89 | 0.050 |
Why?
| | Herniorrhaphy | 1 | 2023 | 87 | 0.050 |
Why?
| | Health Facilities | 1 | 2023 | 85 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2022 | 22 | 0.050 |
Why?
| | Death | 1 | 2023 | 129 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2025 | 640 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 33 | 0.050 |
Why?
| | Papua New Guinea | 1 | 2012 | 10 | 0.050 |
Why?
| | Vomiting | 1 | 2023 | 131 | 0.050 |
Why?
| | Burn Units | 1 | 2022 | 40 | 0.050 |
Why?
| | Breast | 1 | 2023 | 155 | 0.050 |
Why?
| | Cough | 1 | 2023 | 123 | 0.040 |
Why?
| | Community Health Workers | 1 | 2023 | 89 | 0.040 |
Why?
| | Alleles | 1 | 2025 | 907 | 0.040 |
Why?
| | Stroke Volume | 1 | 2025 | 652 | 0.040 |
Why?
| | Cardiology | 1 | 2025 | 363 | 0.040 |
Why?
| | Carotid Arteries | 1 | 2023 | 206 | 0.040 |
Why?
| | Patient Acuity | 1 | 2022 | 46 | 0.040 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 107 | 0.040 |
Why?
| | Demography | 1 | 2022 | 274 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2023 | 778 | 0.040 |
Why?
| | Educational Status | 1 | 2023 | 466 | 0.040 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 68 | 0.040 |
Why?
| | Neurosurgical Procedures | 1 | 2023 | 209 | 0.040 |
Why?
| | Sample Size | 1 | 2021 | 124 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 678 | 0.040 |
Why?
| | Habits | 1 | 2020 | 47 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 238 | 0.040 |
Why?
| | Research Personnel | 1 | 2022 | 190 | 0.040 |
Why?
| | Censuses | 1 | 2020 | 33 | 0.040 |
Why?
| | Gastrectomy | 1 | 2022 | 164 | 0.040 |
Why?
| | Policy | 1 | 2021 | 147 | 0.040 |
Why?
| | Focus Groups | 1 | 2023 | 588 | 0.040 |
Why?
| | Lung | 2 | 2024 | 4122 | 0.040 |
Why?
| | Schools, Medical | 1 | 2021 | 158 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1271 | 0.040 |
Why?
| | Blood Proteins | 1 | 2022 | 239 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 496 | 0.040 |
Why?
| | South Africa | 1 | 2021 | 262 | 0.040 |
Why?
| | Fear | 1 | 2023 | 373 | 0.040 |
Why?
| | Reoperation | 1 | 2023 | 645 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 251 | 0.040 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 50 | 0.040 |
Why?
| | Urination Disorders | 1 | 2019 | 15 | 0.040 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2019 | 12 | 0.040 |
Why?
| | Risk | 1 | 2022 | 920 | 0.040 |
Why?
| | Organoplatinum Compounds | 1 | 2019 | 65 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 371 | 0.040 |
Why?
| | Mentors | 1 | 2021 | 217 | 0.040 |
Why?
| | Leucovorin | 1 | 2019 | 98 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 517 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 508 | 0.040 |
Why?
| | Kenya | 1 | 2019 | 129 | 0.030 |
Why?
| | Cardiovascular Nursing | 1 | 2018 | 5 | 0.030 |
Why?
| | Colombia | 1 | 2018 | 41 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2010 | 267 | 0.030 |
Why?
| | Survivors | 1 | 2022 | 526 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2019 | 162 | 0.030 |
Why?
| | Fluorouracil | 1 | 2019 | 231 | 0.030 |
Why?
| | Drug Combinations | 1 | 2019 | 400 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 2009 | 256 | 0.030 |
Why?
| | Overweight | 1 | 2023 | 614 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2023 | 553 | 0.030 |
Why?
| | Chronic Disease | 1 | 2024 | 1827 | 0.030 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 446 | 0.030 |
Why?
| | Rectum | 1 | 2019 | 180 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1339 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2021 | 561 | 0.030 |
Why?
| | Coinfection | 1 | 2019 | 143 | 0.030 |
Why?
| | Odds Ratio | 1 | 2010 | 1077 | 0.030 |
Why?
| | Mortality | 1 | 2019 | 375 | 0.030 |
Why?
| | Proctitis | 1 | 2016 | 6 | 0.030 |
Why?
| | Urogenital System | 1 | 2016 | 16 | 0.030 |
Why?
| | Caregivers | 1 | 2025 | 1080 | 0.030 |
Why?
| | Viral Load | 1 | 2019 | 526 | 0.030 |
Why?
| | Latin America | 1 | 2016 | 96 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 908 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1160 | 0.030 |
Why?
| | Prisoners | 1 | 2008 | 146 | 0.030 |
Why?
| | Mental Health | 1 | 2023 | 779 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 481 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 858 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 358 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 289 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2017 | 134 | 0.030 |
Why?
| | Sexually Transmitted Diseases | 1 | 2008 | 163 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1125 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 827 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2016 | 149 | 0.030 |
Why?
| | Self Care | 1 | 2018 | 396 | 0.030 |
Why?
| | Plant Extracts | 1 | 2016 | 192 | 0.030 |
Why?
| | Electrocardiography | 1 | 2018 | 667 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 857 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 574 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1730 | 0.030 |
Why?
| | Mutation | 1 | 2025 | 4093 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 970 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 1079 | 0.030 |
Why?
| | Insurance, Health | 1 | 2017 | 318 | 0.030 |
Why?
| | Hemorrhage | 1 | 2019 | 825 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3647 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3416 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2107 | 0.020 |
Why?
| | Health Promotion | 1 | 2008 | 786 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 4340 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2919 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2400 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 3131 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2008 | 313 | 0.020 |
Why?
| | Veterans | 1 | 2009 | 1650 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2009 | 1107 | 0.010 |
Why?
|
|
Colborn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|